David Holtzman, M.D., member of the Cure Alzheimer’s Fund Research Consortium, will receive the 2015 Carl and Gerty Cori Faculty Achievement Award from his home institution, Washington University in St. Louis. The award goes to faculty members who “embody the ideals of individual and collaborative excellence” and “have made significant contributions to their fields,” according to Washington University Chancellor Mark S. Wrighton.
New research by David Holtzman, M.D. at the Washington University School of Medicine points to a sleep regulation protein in the brain as a possible target for Alzheimer's disease treatment or prevention. The protein, called orexin, plays a role in rousing the brain from sleep.
We collected your questions about Alzheimer's from our fall symposium and social media and presented them to Dr. Rudy Tanzi, chairman of our Research Consortium. Watch the videos below!
Brain health is closely intertwined with the health of the rest of the body. In this video, Rudy Tanzi, Ph.D., answers your questions about how things like sleep, exercise levels, and cardiovascular health can relate to Alzheimer's disease.
Rudy Tanzi, Ph.D., answers your questions about which factors in one's lifestyle can raise or lower risk for Alzheimer's.
Missed Part 1 of the Q&A? Click here to watch Alzheimer's and Genetics.
Brain aging is associated with lower production of circadian clock proteins, which synchronize biological processes to light and dark cycles. In Alzheimer’s and other neurodegenerative diseases, circadian dysfunction is commonly observed.
BOSTON – New research examining levels of the hallmark proteins linked to Alzheimer's disease found in patients suffering from post-operative cognitive changes (POCC) may lead to safer surgery care and better post-operative outcomes for senior adults.
The study, led by Cure Alzheimer’s Research Consortium member Sam Gandy, M.D., Ph.D., of the Icahn School of Medicine at Mount Sinai, examined how elements in air pollution such as nickel nanoparticles affect the levels of certain peptides in the brain that are found to be at heightened levels in patients suffering from Alzheimer’s Disease.
“We don’t yet completely understand why the peptides accumulate, but we do know the genes responding to the peptides play an important role in developing Alzheimer’s,” said Gandy.
Traumatic Brain Injury (TBI) can lead to neurodegenerative syndromes that include Alzheimer's Disease (AD) and Chronic Traumatic Encephalopathy (CTE).
The April issue of Nature Reviews Neurology is devoted to Traumatic Brain Injury (TBI) and Chronic Traumatic Encephalopathy (CTE). Cure Alzheimer’s Fund research consortium member, Sam Gandy, M.D., Ph.D., of the Icahn School of Medicine at Mount Sinai is senior author of the lead review and overview.
© 2005-2015 Cure Alzheimer's Fund. All rights reserved.